On September 30, 2019 ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is reported its interim results for the six months ended 30 June 2019 (the "Period") (Press release, ImmuPharma, SEP 30, 2019, View Source [SID1234539903]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key Highlights (including post Period review)

Financials

Stable financial performance over the Period
– Cash balance of £2.3 million as at 30 June 2019 (31 December 2018: £4.9 million)
– Derivative financial asset of £1.9 million as at 30 June 2019 (31 December 2018: nil)
– Loss for the period of £3.9 million (30 June 2018: £4.1 million)
– Research and development expenses of £1.4 million (30 June 2018: £2.5 million)
– Basic and diluted loss per share of 2.80p (30 June 2018: 2.94p)
– Subscription agreement with Lanstead Capital Investors LP raising approximately £2.66 million
• Lanstead retains a holding of over 16% in ImmuPharma
Lupuzor

Open label extension study – Following the completion of LupuzorTM’s Phase III clinical trial in January 2019, ImmuPharma undertook an open label extension study. Analysis of results from Lupuzor’s‘extension’ open label study were announced on 28 June 2019
– 62 eligible patients enrolled throughout the US and Europe completing a 24-week treatment period
– Primary endpoint successfully achieved confirming the safety profile of Lupuzor
– No ‘serious adverse events’ related to Lupuzor reported
– Insights into the Phase III data allow an optimised Lupuzor phase III design to progress
Exploration within the P140 platform for different auto-immune indications outside of lupus continues
Other program developments

Within our two further platforms, Ureka Sarl (Peptide) and Elro Pharma (Nucant) , ImmuPharma continues to explore options to license, divest or ‘spin-off’ the technologies to unlock future potential and enhance value to shareholders
The peer reviewed research journal ‘Nature Communications’ paper published on the proprietary technology Urelix from Ureka – Superior GLP-1 analogues pave way for peptide types across many therapy areas
Negotiations with Incanthera Limited on the Nucant cancer programme and broader collaboration discussions terminated – ImmuPharma retains a 15% shareholding in Incanthera
Industry reports

The Life Sciences Division published an initiation research note on ImmuPharma in May 2019